CMS Diaphanography Coverage Policy 2026: What Billing Teams Need to Know About NCD 258

The Centers for Medicare & Medicaid Services (CMS) has issued a modification to National Coverage Determination (NCD) 258, addressing transillumination light scanning—also known as diaphanography—as a breast cancer detection tool. This update reaffirms CMS's non-coverage stance on diaphanography, citing insufficient clinical evidence to establish the technology's usefulness compared to established breast disease detection methods. For billing teams submitting claims to Medicare, this policy has direct implications for any facility or provider that may be considering this procedure as a billable diagnostic service.

What Is Transillumination Light Scanning (Diaphanography) and Why Does CMS Still Not Cover It?

Transillumination light scanning, or diaphanography, is a non-invasive imaging technique that passes light through breast tissue to detect abnormalities, including potential cancerous lesions. The premise is straightforward: different tissues absorb or transmit light differently, theoretically allowing clinicians to identify masses or structural irregularities without radiation exposure.

CMS's position under NCD 258 is unambiguous: while the procedure appears safe, its clinical usefulness has not been clearly established when compared to existing breast cancer and breast disease detection modalities. In practice, this means mammography, ultrasound, and MRI remain the covered standards—diaphanography does not meet Medicare's threshold for medical necessity.

The modification to NCD 258 does not introduce a new coverage expansion or experimental approval. It is a policy update that maintains and reaffirms the non-coverage determination, signaling that the evidence base CMS requires has not materialized. Billing teams should treat this as a hard stop, not a gray area.

CMS Medical Necessity Standard Under NCD 258

Under NCD 258, CMS has determined that further study of transillumination technology is needed before any coverage determination can be made in its favor. The policy language is explicit: "Program payment may not be made for this procedure at this time."

This language places diaphanography firmly in non-covered territory for Medicare beneficiaries—not as an experimental or investigational designation in the traditional sense, but as a procedure that has simply failed to demonstrate comparative clinical value against existing covered alternatives. The distinction matters for how your team documents and responds to patient inquiries about out-of-pocket responsibility.

There are no listed exceptions, no indication-specific carve-outs, and no prior authorization pathway that would make this procedure payable under Medicare. Providers cannot obtain authorization to bill Medicare for diaphanography regardless of clinical circumstances or patient presentation.

Affected Codes

The policy does not list specific CPT or HCPCS codes applicable to this NCD. Billing teams should note that the absence of assigned codes does not create ambiguity about coverage—the NCD's plain-language prohibition applies to the procedure itself. If your practice management or encoder software generates a code associated with diaphanography or transillumination light scanning, do not submit that claim to Medicare.

Not Covered Under Medicare:

Related ICD-10 Diagnosis Codes:

No ICD-10-CM codes are specified in the policy data. Providers should be aware that no diagnosis code—including breast mass (N63.x), family history of breast cancer (Z80.3), or screening encounters (Z12.31)—creates a pathway to Medicare reimbursement for this procedure. Medical necessity documentation does not override an NCD non-coverage determination.

Prior Authorization Requirements Under NCD 258

There are no prior authorization requirements listed under NCD 258 because prior authorization is not applicable to non-covered services. CMS does not offer a PA pathway for procedures excluded from coverage by NCD. Submitting a prior authorization request for diaphanography would not generate approval and would not create any billing entitlement.

If a patient specifically requests diaphanography and has Medicare as their primary payer, the appropriate response is an Advance Beneficiary Notice of Noncoverage (ABN). An ABN informs the patient that Medicare will not pay for the service and gives them the option to proceed and accept financial responsibility. Without a properly executed ABN, the provider assumes the financial risk.

How This Affects Breast Imaging and Oncology Billing

For most high-volume breast imaging centers and radiology practices, diaphanography is not a routine part of the service menu. However, NCD modifications like this one are worth tracking because they occasionally signal CMS reconsideration of a technology—and because policy reaffirmations can accompany updated claims processing instructions that affect how legacy claims are audited.

OB/GYN practices, general surgery groups, and oncology offices that may offer or refer for breast diagnostics should confirm their billing staff is aware that any transillumination-based service falls outside Medicare's covered benefit. This is especially relevant if new vendors or device manufacturers are marketing updated versions of diaphanography technology as clinically differentiated—CMS's NCD applies to the procedure category, not just legacy equipment.

Revenue cycle directors should also flag this NCD for any value-based care contracts where Medicare beneficiary claims are bundled or attributed. A non-covered procedure billed in error can trigger compliance exposure beyond simple claim denial.

What Your Billing Team Should Do